Kontoor Brands offers attractive normalized earnings growth and shareholder returns through Wrangler, Helly Hansen, and portfolio simplification, although integration execution, apparel cyclicality, and leverage remain important risks.
Buy-rated reports
511 tickers rated BuyPaylocity combines sticky payroll software, strong cash generation, and expanding enterprise workflows with a relatively attractive valuation, although slower growth and intense HCM competition could constrain future returns.
NNN REIT offers durable triple-net rental cash flows, a 37-year dividend-growth record, and an attractive income yield, although interest-rate sensitivity, tenant credit risk, and acquisition-related dilution constrain upside.
Texas Pacific Land combines scarce Permian mineral rights, exceptional cash generation, and infrastructure monetization opportunities, but commodity exposure and demanding growth expectations limit the margin of safety.
Marathon Petroleum combines large-scale refining, valuable MPLX cash flows and aggressive shareholder returns at a moderately attractive valuation, although exceptional refining margins could normalize and sharply reduce earnings.
Assurant combines recurring specialty insurance and protection-service earnings with strong cash generation and disciplined buybacks, although catastrophe exposure, partner concentration, and a higher share price constrain its margin of safety.
Neurocrine combines strong commercial cash generation with growing rare-disease franchises and promising psychiatric pipeline assets, although INGREZZA concentration, acquisition economics, and clinical failures remain key risks.
Viper Energy offers high-margin Permian royalties, visible production growth and attractive normalized cash-flow valuation, although oil-price volatility, acquisition dilution and controlling-shareholder governance remain material risks.
Q2 combines sticky digital banking subscriptions, double-digit recurring growth, and expanding cash flow, offering attractive long-term compounding potential, although competition, SBC dilution, and implementation delays remain key risks.
Parsons offers discounted exposure to long-term defense technology and infrastructure demand, supported by record backlog and resilient cash flow, although federal contract volatility and weak capital returns could delay earnings recovery.
Stryker combines a durable medical-device franchise, strong cash generation and a historically compressed valuation, but weaker guidance, cybersecurity exposure and acquisition impairments challenge near-term earnings confidence.
Itron offers durable smart-grid infrastructure exposure, growing recurring software revenue and attractive cash-flow valuation, although acquisition execution and uneven utility deployment cycles could constrain earnings growth.